1. Home
  2. LPSN vs PLUR Comparison

LPSN vs PLUR Comparison

Compare LPSN & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LivePerson Inc.

LPSN

LivePerson Inc.

HOLD

Current Price

$2.39

Market Cap

32.3M

Sector

Technology

ML Signal

HOLD

Logo Pluri Inc.

PLUR

Pluri Inc.

N/A

Current Price

$3.32

Market Cap

33.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LPSN
PLUR
Founded
1995
2001
Country
United States
Israel
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
32.3M
33.9M
IPO Year
2000
2001

Fundamental Metrics

Financial Performance
Metric
LPSN
PLUR
Price
$2.39
$3.32
Analyst Decision
Hold
Strong Buy
Analyst Count
1
1
Target Price
N/A
$12.00
AVG Volume (30 Days)
153.8K
5.6K
Earning Date
03-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
10.78
EPS
N/A
N/A
Revenue
$249,838,000.00
$1,336,000.00
Revenue This Year
N/A
$97.38
Revenue Next Year
N/A
$293.97
P/E Ratio
N/A
N/A
Revenue Growth
N/A
309.82
52 Week Low
$0.39
$2.82
52 Week High
$7.54
$7.13

Technical Indicators

Market Signals
Indicator
LPSN
PLUR
Relative Strength Index (RSI) 36.88 50.13
Support Level $0.83 $3.13
Resistance Level $3.43 $3.42
Average True Range (ATR) 0.17 0.15
MACD -0.01 0.01
Stochastic Oscillator 6.04 63.27

Price Performance

Historical Comparison
LPSN
PLUR

About LPSN LivePerson Inc.

LivePerson Inc is the enterprise leader in digital customer conversation. The Conversational Cloud, the Company's enterprise-class digital customer conversation platform, is trusted by the world's top brands to accelerate their contact center transformation, orchestrate conversations across all channels, departments, and systems, increase agent productivity, and deliver more personalized, AI-empowered customer experiences. The company has a presence in the United Kingdom, Asia-Pacific, Latin America, and Europe.

About PLUR Pluri Inc.

Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.

Share on Social Networks: